Discover the Power of Innovation at the Seoul National University Pavilion | BIO International 2025, Boston Join us in Boston at BIO 2025 and experience the forefront of biomedical innovation through the Seoul National University (SNU) Pavilion, where academic excellence meets translational impact. At the SNU R&DB Foundation, we champion world-class research by managing intellectual property, accelerating technology transfer, and advancing commercialization. We foster interdisciplinary collaboration, empower academia-industry partnerships, and nurture entrepreneurial growth among SNU’s researchers and students. At Booth #2879, we are proud of presenting a curated selection of next-generation technologies available for global licensing and collaboration, including: • First-in-class small molecules and antibodies targeting liver cancer and MASH • Novel peptides with superior hair growth efficacy • Broad-spectrum antibiotics with powerful efficacy against multidrug-resistant superbugs, developed through drug repositioning • Short peptides with a new mode of action offering both anti-inflammatory and anti-cancer effects, including IBD • Next-generation mesothelin-targeting antibody engineered to overcome proteolytic degradation; and • More game-changing innovations shaping the next era of biotechnology. Explore the future of Korean biotech through seven innovative SNU spin-off companies, each pushing the boundaries of science and commercialization: AIGENDRUG | AI-driven drug discovery platform(DrugVLAB) | www.aigendrug.com CellBion | Radiopharmaceuticals & radioligand therapy | www.cellbion.co.kr CELLinCELLS | Organoid tissue module manufacturing technology | www.cellincells.com ClichemBIO, Inc. | Albumin-based nano theranostics platform for precision nano-medicine | www.clichembio.com Molecular Innovations Inc. | Multifunctional small molecules (Resveratron) for improving skin health and metabolic diseases NIBEC | Proprietary peptides, regenerative biomaterials, and drug delivery systems | https://nibec.co.kr/en/ Portrai | Spatial Transcriptomics-based Drug Discovery Solutions and AI Pathology Analysis System | www.portrai.io We cordially invite you to visit the SNU Pavilion and explore powerful opportunities for partnership, co-development, and strategic investment. Let’s build the future of biotech—together. Meet us in Boston, and let innovation begin. | Seoul National University (SNU) Pavilion | BIO International Convention 2026 Discover Partner-Ready Innovation from One of Asia’s Leading Research Universities Join the Seoul National University (SNU) Pavilion at BIO 2026 and connect with a premier hub of translational research and global partnering. Backed by a strong track record in intellectual property management, technology transfer, and successful commercialization, the SNU R&DB Foundation serves as the gateway to high-impact biomedical innovations from Korea’s top-ranked university. We actively collaborate with global pharmaceutical and biotech partners to advance early-stage assets toward clinical and commercial success. Our portfolio is built on rigorous science, validated targets, and strong IP positions—designed for efficient licensing and co-development. We will be showcasing selected innovations at Booth #5535 ○ Hepatitis B virus-derived polypeptides and their therapeutic applications ○ An antibacterial or antifungal composition for preventing or treating bacterial or fungal infections (featuring VLX600) ○ Anti-AXL (and Anti-MERTK) antibody and composition containing the same ○ Novel isoxazole compounds as TM4SF5-specific inhibitors and their therapeutic applications ○ Fc Variants for Modulating FcRn Function ○ Novel CD89(Fc α receptor) binding antibodies and their therapeutic applications Explore a curated lineup of innovative SNU spin-off companies, each advancing breakthrough science toward real-world impact and global commercialization. ○ AIGENDRUG | AI Drug Discovery Platform(DrugVLAB) ○ CellBion | Radioligand therapeutics and diagnostics for prostate cancer ○ CELLinCELLS | 3D Tissue Reforming Technology Platform technology, TRTP-101, TRTP-20X ○ ClichemBIO, Inc. | Albumin nanoplatform, New Drug Development ○ NIBEC | Medical Device, Pepetide CDMO, Peptide-based therapeutics ○ SJChem Meditech, Inc | Oral Drug for Atopic Dermatitis ○ Qureator, Inc. | Curiochips®, Human Disease Models, QuriCore AI™ Platform Meet our team to explore partnership opportunities aligned with your pipeline strategy. Pre-arranged meetings are highly encouraged for in-depth discussions and confidential data sharing.
SEKISUI
BioProduction by SEKISUI describes SEKISUI’s contract service offering as a microbial focused CDMO with expertise in proteins and downstream purification. Our fermentation process development and production experience helps smooth technical transfer and process scale up. Our core competencies include E.coli and yeast fermentation, plant protein extraction, large scale bioprocessing, protein purification, bulk formulation, lyophilization and analytical testing. Our production site in the UK has been a leader in the manufacturing of high-quality proteins and specialty biochemicals globally to the healthcare market for over 40 years. We have worked with many global partners to supply high quality materials for a variety of applications, including proteins for biotherapeutics, pharmaceuticals, and diagnostic medical devices. | SEKISUI Medical Group is a diverse, global network consisting of a diagnostics business and pharmaceutical sciences business which spans drug development services and manufacturing, including active pharmaceutical ingredients and pharmaceutical intermediates, amino acids, as well as a wide range of enzymes for use in diagnostics, and biopharmaceutical contract manufacturing and more BioProduction by SEKISUI is a trusted provider of specialized CDMO services, offering biomanufacturing solutions built on decades of experience in microbial fermentation and downstream processing. We support the full development lifecycle—from strain optimization to clinical-scale manufacturing—catering to a wide range of biologics including enzymes, recombinant proteins, antibody fragments, viral vectors, and plasmids. Our microbial expertise spans multiple expression platforms including E. coli, Pichia pastoris, Bacillus, Streptomyces, Streptococcus, fungi, and yeast, enabling highly flexible and efficient process development for biologics. Our advanced UK facility based in Kent is equipped for full spectrum biomanufacturing services and features: Fermentation capacity from 2 L R&D scale up to 5,000 L production Integrated protein expression services for high-yield production Advanced chromatography and purification suites End-to-end antibody production services Lyophilization and bulk formulation GMP-aligned systems under ISO 9001 and ISO 8 cleanroom classifications In-progress GMP plasmid manufacturing and clinical-grade expansion Environmental control and zero-emissions sustainability framework We also provide expert plasmid production for research and therapeutics, with growing capabilities in viral vector manufacturing for cell and gene therapy markets. As established recombinant protein manufacturers, we support custom expression and scale-up for diverse biopharmaceutical programs. In cell and gene therapy, SEKISUI is committed to enhancing the reliability, scalability, and efficiency of cell culture. Ceglu™, our lead technology, is a chemically defined, synthetic matrix that provides a stable, feeder-free environment for culturing stem cells (iPSCs, ESCs, MSCs). To accommodate diverse workflows, Ceglu™ is available in two formats: ready‑to‑use pre‑coated culture ware for research workflows, and an automation‑friendly coating solution for cell manufacturing workflows which can be precoated and sterilized onto closed systems or bioreactor consumables for seamless cell production. With a focus on advancing regenerative medicine, SEKISUI partners with service providers, biopharma organizations, bioprocessing innovators and academia to deliver solutions that meet the evolving needs of the industry. Drop by our booth 5621 to ask us about our GMP-readiness, room temperature storage and iPSC.
SCIWIN Laboratories Co., Ltd
Custom Organic Synthesis Biopharmaceutical Providing CRO & CMO services for API manufacturers and new drug companies ADC-Novel linker-Payloads Organic synthesis-Small molecule & macromolecule Custom synthesis-reference & impurity standard Technology transfer-Lab to GMP manufacturer Professional Custom Synthesis Services to Meet Your Drug Development Needs SCIWINLAB specializes in providing high-quality custom synthesis services, covering synthesis and process development from small-scale (milligram-level) to large-scale (kilogram-level) production. Our R&D team possesses 10 to 20 years of GMP experience in the pharmaceutical industry, excelling in process optimization and ensuring smooth technology transfer to GMP facilities for scale-up production. With our expertise in organic synthesis, we are committed to delivering reliable and efficient solutions to our clients. To date, we have successfully assisted multiple pharmaceutical companies in transferring technology to GMP facilities, completing the scale-up of five products, and accelerating their market entry. | Custom Organic Synthesis Providing CRO Contract Manufacturing Organization) & CMO (Contract Development and Manufacturing Organization) services for API (Active Pharmaceutical Ingredients) manufacturers and new drug companies ADC-Novel linker-Payloads Organic synthesis-Small molecule & macromolecule Custom synthesis-reference & impurity standard Technology transfer-Lab to GMP manufacturer
Richter BioLogics GmbH
Richter BioLogics stands at the forefront of Germany’s contract development and manufacturing sphere, with a specialized focus on products derived from bacteria and yeasts. Our three facilities boast capacities of 2 x 1,500L and 2 x 300L, facilitating the production of plasmid DNA, antibodies, including VHH/nanobodies, proteins, and vaccines. With over 35 years of proven success, our highly skilled teams are dedicated to supporting clients through every stage of production. We offer robust process development, supply products for clinical trials, oversee commercial production, conduct in-house quality control testing, and provide QP release. Our commitment to excellence is reflected in our adherence to the highest pharmaceutical quality standards, as verified by major regulatory bodies such as EMA, FDA, ANVISA, PMDA, and MFDS, alongside numerous customer audits. At Richter BioLogics, we pride ourselves on delivering reliable solutions with precision and expertise, ensuring our partners achieve their clinical and commercial goals with confidence. | Richter BioLogics stands at the forefront of contract development and manufacturing (CDMO) sphere, with a specialized focus on products derived from bacteria and yeasts. Our three facilities boast capacities of 2 x 1,500L and 2 x 300L, facilitating the production of antibodies, including VHH/Nanobodies, proteins, vaccines and plasmid DNA. With over 35 years of proven success, our highly skilled teams are dedicated to supporting clients through every stage of production. We offer robust process development, supply products for clinical trials, commercial production, conduct in-house quality control testing, and provide QP release. Our commitment to excellence is reflected in our adherence to the highest pharmaceutical quality standards, as verified by major regulatory bodies such as EMA, FDA, ANVISA, PMDA, and MFDS, alongside numerous customer audits. At Richter BioLogics, we pride ourselves on delivering reliable solutions with precision and expertise, ensuring our partners achieve their clinical and commercial goals with confidence and in time.
Resilience
Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines (biologics, vaccines, nucleic acid, cell therapy, and gene therapy modalities). Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions. For more information, visit https://resilience.com/ and follow us on social media: @IncResilience on Twitter and Resilience on LinkedIn. | Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at-scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions. | Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines (biologics, vaccines, nucleic acid, cell/ gene therapy modalities and drug product). Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions. For more information, visit https://resilience.com/ and follow us on social media: @IncResilience on Twitter and Resilience on LinkedIn.
Pyramid Labs
SFF CDMO Aseptic Fill/Finish Services. Vial and Syringe Filling Lyophilization Analytical Services In-house Bioburden & Sterility Clinical & Commercial Manufacturing Stability Services Clinical & Commercial Labeling Breakloose/Glide Force testing. PPQ High Recovery Vials HRV US based manufacturing sites Drug Product CMC 510k Biologics mAb oligonucleotides peptides small molecules siRna nanoparticles Parenteral filling | Pyramid Pharma Services is a U.S.-based clinical-to-commercial fill-finish CDMO with over 26 years of GMP drug product manufacturing experience and more than 35 years in business. We provide aseptic manufacturing and sterile manufacturing solutions for complex injectable drug products, supporting both emerging biotech and established pharmaceutical companies. Our expertise includes oligonucleotides, peptides, biologics, and advanced therapeutics, with integrated capabilities that span formulation development, aseptic fill-finish, lyophilization, prefilled syringe and cartridge filling, device assembly, labeling, packaging, and analytical services. By offering end-to-end drug product manufacturing within a single organization, we reduce complexity, accelerate timelines, and ensure consistent execution from clinical development through commercial supply. Pyramid’s California-based facilities support flexible manufacturing across a range of batch sizes and delivery formats, including vials, prefilled syringes, and cartridges. Ongoing investment in advanced, high-speed fill-finish infrastructure strengthens our ability to deliver scalable, reliable solutions for increasingly complex injectable therapies. Our track record includes over 100 successful IND-enabling programs, multiple commercial products, and a strong history of FDA inspections—demonstrating a consistent focus on quality, compliance, and execution. As a fill-finish CDMO, we partner closely with our clients’ CMC, technical, and regulatory teams to support efficient development and commercialization. We work with companies developing injectable therapies that require a reliable, experienced partner for sterile fill-finish and aseptic drug product manufacturing. If you are advancing a program and evaluating a CDMO for fill-finish or drug product manufacturing, we welcome the opportunity to connect at BIO 2026. Schedule time with our team to discuss your program.
PSC Biotech
Founded in 1996, PSC Biotech Corporation is a global organization that has spent over two decades providing life science services and solutions through our professional service consultancy for CQV, CSV, auditing, IT services, and much more. PSC Software provides inspection/audit management and eQMS services and BioTechnique provides CRDMO services. We also distribute equipment (Lives International data loggers and thermal mapping systems). Since its inception, PSC has served as a strategic partner to emerging and established life science companies, helping them bring their life-saving products to market. | PSC Biotech® is a global specialty life sciences consultancy firms, supporting over 1000 clients in more than 35 countries. PSC Biotech Corporation® provides life science services and solutions through our professional service consultancy (CQV, CSA/CSV, Audit, and much more.) PSC Software® provides inspection management and electronic quality management systems that enable businesses to stay compliant while effectively and efficiently delivering products to market. PSC Software® has 4 proprietary, 21 CFR Part 11 compliant, cloud-based systems that accelerate and streamline quality processes. BioTechnique® is a division of PSC Biotech Corporation®. BioTechnique® is a Contract Research, Development, and Manufacturing Organization (CRDMO) that provides lyophilization and therapeutic sterile injectable fill-finish solutions to cater to both large and small investigational/clinical stage or commercial batch sizes. BioTechnique® provides a comprehensive platform for success, beginning with Formulation Studies, extending through Analytical and Formulation Development, and culminating in Product Launch (clinical or commercial). | . | BioTechnique is a CRDMO, pharmaceutical manufacturing facility located in York, PA. A highly potent sterile injectable and clinical oncolytics manufacturing company dedicated to providing cytotoxic and high potency sterile injectable fill-finish services. Our project management and client services staff work closely with clients to meet all their manufacturing needs. We provide formulation and compounding, fill-finish, lyophilization, shipping, storage, and 3rd party logistics for a wide variety of liquid injectables. BioTechnique utilizes our expertise to create process designs for client product needs. To learn more, visit www.biotechnique.com
ProJect Pharmaceutics (PJP)
PJP is the go-to specialist in formulation and process development across complex biologics, bioconjugates, and other therapeutic modalities. Our development agility spans liquid, frozen, and lyo formats in vials, cartridges, or pre-filled syringes and in-step or independent from your chosen manufacturer. Let’s solve your formulation and process challenges together.
Polish Investment & Trade Agency
The Polish Investment and Trade Agency is a mission driven, government entity, that is dedicated to promoting and growing the economy of Poland on a global stage. Anchored in Warsaw, with a network of nearly 60 foreign trade offices around the world, the Agency’s mission is to increase the awareness of Polish brands in international markets and to promote national products and services. This mission is accomplished by three pillars: promoting Polish exports, supporting the inflow of foreign direct investments to Poland and the implementation of Polish investments in the country, and the cultivation of partnerships with domestic and international stakeholders. | . | The Polish Investment and Trade Agency (PAIH) is Poland’s leading government agency dedicated to promoting Polish business on the international stage and attracting foreign investment to Poland. As a key partner for international companies looking to explore opportunities in Poland, PAIH provides comprehensive support to exporters and investors, bridging connections between global markets and the dynamic Polish economy. At the BIO International Convention, PAIH proudly coordinates the Polish National Pavilion, a platform showcasing Poland’s innovation potential in the life sciences sector. In collaboration with BioForum Central European Life Science Cluster, this year’s booth features 26 outstanding Polish companies representing the strength, diversity, and international ambitions of Poland’s biotech ecosystem. At this year’s BIO International Convention, Polish exhibitors will present cutting-edge solutions across four key categories: Drug Development, Diagnostics, Manufacturing, and Digital Solutions and Services. We invite all BIO International Convention participants to visit the Polish National Booth, meet our innovative companies, and explore partnership opportunities across the biotech value chain—from early-stage research and diagnostics to digital transformation and advanced manufacturing. | xxxx